Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The Chicago-based imaging systems manufacturer will pay the purchase price in cash, acquiring the company from private equity firm Trilantic North America.
Researchers are developing a system that combines a universal radioactive building block with different biological molecules to create new radiotracers.
The software supports amyloid, tau and FDG PET and provides automated Centiloid measurements for amyloid imaging and CenTauR measurements for tau imaging.
The launch comes ahead of meetings with members of Congress this fall in Washington, D.C., where group leaders plan to advocate for the availability of cardiac PET, particularly among underserved populations.
The finalized project was designed to increase production capacity and support growing demand for PET/CT technology, including new product lines planned for the United States and international markets.
According to new research, gliomas—a deadly group of brain tumors that are difficult to treat—have increased folate receptor expression, meaning they also show increased uptake of folate-based radiopharmaceuticals on PET imaging.
The recent CMS coverage determination did not make any mention of beta-amyloid PET imaging that is necessary for both diagnosing Alzheimer’s and monitoring the effectiveness of related treatments.
The findings support adopting F-18 DCFPyL PET/CT as the standard of care for prostate cancer staging, authors of a new Scientific Reports paper concluded.
Rather than administering radiolabeled glucose for exams, imagers give patients a small amount of a harmless glucose solution that is said to be equivalent to a can of a carbonated drink.
Difficulty obtaining PET/CT scans was reported by 55% of respondents, with 21% citing this as the greatest barrier in treating classic Hodgkin lymphoma.